Navigation Links
Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
Date:10/24/2007

Tumor shrinkage observed in nearly 80% of patients

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported encouraging data from an ongoing phase 2 trial of XL880, an inhibitor of MET and VEGFR2 kinases, in patients with papillary renal cell carcinoma (PRC). Of 19 patients with measurable disease evaluable for tumor responses, 15 (79%) have had a decrease in tumor size (4-33%), including one patient with a partial response. All 19 evaluable patients with at least one post-baseline tumor assessment have had stable disease for at least three months, including 12 patients with stable disease for six months to 15+ months. Results of preliminary analyses of plasma biomarkers and tumor samples are consistent with inhibition of angiogenesis and proliferation and an increase in apoptosis. Data were presented today in a poster session (Abstract #B249) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 22-26, 2007 in San Francisco.

"The phase 2 trial of XL880 in PRC was supported both by the biology of the disease, which frequently is associated with activating mutations or amplifications in MET, and the favorable responses observed in patients with PRC in the reported phase 1 study of the compound," said Michael Morrissey, Ph.D., Exelixis' president of research and development. "We believe that today's data, which show that the significant majority of patients on study have experienced tumor shrinkage with prolonged duration of stable disease, highlight the potential utility of XL880 and its potent effects in modulating both MET and VEGFR2 in the clinical setting. We are excited about the potential
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Today, Siemens (NYSE: SI ) announces ... Medical Informatics Officer (CMIO), of the Health Services (HS) Business ... Health Information Exchange (IHIE), Marc recently served as ... role at Siemens, Marc will be responsible for clinical informatics ...
... 21, 2011 From the floor of the HIMSS11 ... MDRX ) today demonstrated native integration between its ... (EHR) and the Allscripts Enterprise and ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS 2Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS 3Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS 4Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS 5
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down reports ... Finals and 3rd place World Cup Match between ... place match will take place on Saturday, July 12th at ... World Cup Finals will take place on Sunday, July 13th ... de Janiero. All tickets for the 2014 World Cup are ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... who was thought to be cured by immediate and aggressive ... of the AIDS-causing virus in her bloodstream, disappointed federal officials ... old, had remained virus-free even though she stopped taking HIV ... her remission would open the door to a functional cure ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines ... analysis and revenue forecast. The well intervention services market in ... 2013 to $3.4 billion by 2018, at a CAGR of ... of the Europe Well Intervention Market report, to get an ... glimpse of the segmentation in the Europe well intervention market, ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... Montana Governor Brian Schweitzer, Chair of the Democratic ... former DGA Chair Gov. Kathleen Sebelius as Secretary of ... broken, and Governor Kathleen Sebelius is an excellent choice ... said. "In reforming our health care system, Governor Sebelius ...
... executive officer of B. E. Smith, recently was honored for ... Most Influential Headhunters" list. Smith,s detailed BusinessWeek profile may be ... ... Lexena, KS (PRWEB) February 28, 2009 ...
... search results on Google and Yahoo? Appearing as if it ... Diego Union Tribune article "Can,t buy me love," appears in ... the presses. Valenti International feels the time is ... were quiet and wanted to avoid dragging our business and clients ...
... better awareness of how machines work , , FRIDAY, Feb. ... sidewalk quicker and easier, but those who use them ... injuries and accidental amputations, say medical experts. , "The ... type of injuries that can be reconstructed," said Dr. ...
... Chicago,s Institute for Health Research and Policy have been ... Cancer Institute to study the link between body fat ... that obese men with prostate cancer have a higher ... their tumor grade and stage at diagnosis. , The ...
... finds patient-physician relationship is entitled to ... In a legal victory that ... competition, an Arkansas state court has ... hospital system, acted improperly by inappropriately ...
Cached Medicine News:Health News:Doug Smith Named One of BusinessWeek's "World's Most Influential Headhunters" 2Health News:Valenti International Responds to the San Diego Union Tribune Article 'Can't buy me love,' Fraught With Inaccuracies and Slanted for Sensationalism, Journalistic Integrity Appears Lost. 2Health News:Valenti International Responds to the San Diego Union Tribune Article 'Can't buy me love,' Fraught With Inaccuracies and Slanted for Sensationalism, Journalistic Integrity Appears Lost. 3Health News:Valenti International Responds to the San Diego Union Tribune Article 'Can't buy me love,' Fraught With Inaccuracies and Slanted for Sensationalism, Journalistic Integrity Appears Lost. 4Health News:Snowblower Hand Injuries Often Extensive, Study Finds 2Health News:UIC receives $3 million to study prostate cancer risk factors 2Health News:Physicians Hail Arkansas Court Victory Against Baptist Health 2
... painfree therapy stimulates the spincter and ... contractions and relaxation. By use of ... surgical operations (bladder liftings) may be ... can improve unsatisfying results. DETRUSAM intravesical ...
... Stepper Template Set is the HDR solution ... implantation technique. The template set consists of ... be sutured to the patient and is ... ultrasound Grid Face Plates. The Stepper Holder ...
... is designed for use with the ... prostate brachytherapy. Please be sure that ... the graphics on the Reusable Template. ... from lower surface which fits into ...
Table mount stabilizer system...
Medicine Products: